
Bright Heart is a medical technology company focused on improving fetal heart screening through AI-enabled precision. Their innovative AI system, developed from over 50,000 ultrasound studies, assists clinicians in detecting signs of congenital heart disease in fetal ultrasounds. By providing valuable information for informed decision-making and seamless integration into existing workflows, Bright Heart aims to reduce the uncertainty surrounding congenital heart diseases, which are the most common birth defects globally. With approximately 1.35 million babies born with congenital heart defects each year, their technology addresses a critical need in prenatal care.

Bright Heart is a medical technology company focused on improving fetal heart screening through AI-enabled precision. Their innovative AI system, developed from over 50,000 ultrasound studies, assists clinicians in detecting signs of congenital heart disease in fetal ultrasounds. By providing valuable information for informed decision-making and seamless integration into existing workflows, Bright Heart aims to reduce the uncertainty surrounding congenital heart diseases, which are the most common birth defects globally. With approximately 1.35 million babies born with congenital heart defects each year, their technology addresses a critical need in prenatal care.
Sector: Medtech — AI for fetal heart ultrasound
Headcount: 18 employees
Funding: Seed ~€2M (May 2023)
Lead investor: Sofinnova Partners
Prenatal diagnosis of congenital heart disease via fetal ultrasound
Medical devices / Healthtech
€2,000,000
Seed round to advance technology development, regulatory preparation, and team expansion.
“Sofinnova Partners led seed investment”